Novartis' PI3K Strategy Expands with Synnovation Acquisition

Novartis buys Pikavation and SNV4818 for $2B upfront + $1B milestones, closing expected first half.
40% of HR+/HER2- breast cancer patients with PIK3CA mutations need better-tolerated PI3K therapies due to toxicity of existing PI3Kα inhibitors.
SNV4818 shows strong activity against PIK3CA mutations in Phase 1/2 trial with fulvestrant/palbociclib, results due 2027.
Acquisition follows pressure on Piqray from Roche's Itovebi, causing Novartis shares to drop 1.02% to $146.68.
If successful, SNV4818 could improve tolerability, enable earlier combinations, and expand options, aligning with Novartis' precision-medicine and oncology strategy, including Kisqali.

Acquisition | Pharmaceutical | Oncology

6 hours ago